This approach may be the mainstay of new combinations of treatments, with additional agents targeting components of other pathways (e.g., PI3K, AKT, mTOR, or TGFβ), including immune system effectors of the tumor microenvironment. This evidence concerns the gene MTOR and neoplasm.